AMGEN Inc

NASDAQ: AMGN
$321.41
-$0.39 (-0.1%)
Real Time Data Delayed 15 Min.

AMGN Articles

Amgen shares saw a nice bump after the FDA on Thursday approved its preventive treatment of migraine in adults.
The April 30 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates in May.
The April 13 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
24/7 Wall St. has put together a preview of AbbVie, Eli Lilly and some of the other top pharma and biotech companies reporting their latest quarterly results in the coming week.
Rheumatoid arthritis is an autoimmune disease that attacks tissues within the joints, and it is a major target of U.S. and foreign biotechnology and pharmaceutical companies.
The March 29 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
The March 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates for the rest of March.
The February 28 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of March.
The short interest data are out for the most recent settlement date, February 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big...
These five stocks come with upward earnings revisions and the potential for rising dividends. They all make good sense for investors looking for stocks ideas as we get closer to the second quarter.
With indiscriminate selling absolutely punishing some of the top large cap biotech stocks, one analyst says now is the time to buy.
The January 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.